Evidence map›Paper›PMID 38158242›Full record

ReviewHematology/oncology clinics of North America2024

Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.

Zainul S Hasanali, Beatrice Razzo, Sandra P Susanibar-Adaniya, Alfred L Garfall, Edward A Stadtmauer, Adam D Cohen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zainul S HasanaliDivision of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
Beatrice RazzoDivision of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
Sandra P Susanibar-AdaniyaDivision of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
Alfred L GarfallDivision of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
Edward A StadtmauerDivision of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
Adam D CohenDivision of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA. Electronic address: Adam.Cohen@pennmedicine.upenn.edu.

Funding

CANCER RESEARCH TRAINING PROGRAMT32CA009615 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty, MICHAEL D HOGARTY · 1988 to 2026
$10.4M
BMT CTN Core- University of Pennsylvania Abramson Cancer CenterUG1HL069286 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Edward A Stadtmauer · 2017 to 2026
$2.0M
Anti-Sox2 immunotherapy to prevent multiple myeloma relapseR21CA238108 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GARFALL, ALFRED L. · 2020 to 2020
$424k
NCI NIH HHS R21 CA238108NHLBI NIH HHS UG1 HL069286
6 · The paper itself

Abstract

Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions.

Indexed as

Multiple MyelomaReceptors, Chimeric AntigenB-Cell Maturation AntigenHumansImmunotherapy, AdoptiveT-LymphocytesB-Cell Maturation AntigenReceptors, Chimeric AntigenB cell maturation antigen (BCMA)Chimeric antigen receptor Tcells (CARTs)Cytokine release syndrome (CRS)Multiple myelomaRelapsed/refractory multiple myeloma

Identifiers

PMID38158242
PMCPMC11000527

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.